Browse by Poster Author

iwCLL X / Twitter

Browse by Poster Author

Type here to filter the list

F
Fürstenau, Moritz

Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne and Duesseldorf, German CLL Study Group, Faculty of Medicine and University Hospital Cologne, University of Cologne
1442 - NGS-based MRD assessment refines prognostication after venetoclax-based first-line combinations for chronic lymphocytic leukemia: A prospective analysis of the phase 3 GAIA/CLL13 trial
Moritz Fürstenau
Favorite
1515 - Re-Treatment with Venetoclax-Obinutuzumab after time-limited, MRD-guided Venetoclax-Obinutuzumab: final analysis of 7 patients with chronic lymphatic leukemia (CLL) treated in the CLL2-BAG trial of the GCLLSG.
Moritz Fürstenau
Favorite
Fabre, Shannon

BeOne Medicines Ltd
1525 - Updated Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the Ongoing Phase 1 CaDAnCe-101 Study
Shannon Fabre
Favorite
Facchinelli, Davide

Hematology Unit, ULSS8 San Bortolo Hospital
1602 - Venetoclax in combination with chemotherapy in Richter Syndrome patients: a real-life experience
Davide Facchinelli
Favorite
Fagerholm, Susanna

Molecular and Integrative Biosciences Research Program, Faculty of Biological and Environmental Sciences, University of Helsinki, Helsinki, Finland.
1221 - The Integrin Adaptor Kindlin-3 Regulates Chronic Lymphocytic Leukemia Development and Progression
Susanna Fagerholm
Favorite
Fais, Franco

Department of Experimental Medicine, University of Genoa, Genoa, Italy; IRCCS Ospedale Policlinico San Martino
1304 - Linking Cytokine Signaling and Metabolism in Chronic Lymphocytic Leukemia: The Translational Relevance of the IL-12 Family
Franco Fais
Favorite
1805 - Targeting the p53/xCT/GSH axis with PRIMA-1Met combined with Sulfasalazine shows therapeutic potential in Chronic Lymphocytic Leukemia
Franco Fais
Favorite
Fakhri, Bita

Stanford Cancer Institute, Stanford University
1110 - Clinical Profiles of Chronic Lymphocytic Leukemia Patients with SF3B1 Mutations: A Single-Institution Study
Bita Fakhri
Favorite
1707 - Evaluating CLL/SLL Clinical Trials: A Participation-to-Prevalence Analysis Using Institutional and SEER Data from 2012-2024
Bita Fakhri
Favorite
1803 - Real-world Treatment Outcomes among Patients with High-Risk CLL/SLL Receiving Venetoclax-Based Therapy in 1L or 2L: An Updated International Study
Bita Fakhri
Favorite
Fang, Xiaosheng

Shandong Provincial Hospital Affiliated to Shandong First Medical University
1020 - KRAS^G13D-Dependent PI3K/AKT Signaling Regulates Fatty Acid Oxidation in Chronic Lymphocytic Leukemia
Xiaosheng Fang
Favorite
1213 - Characterizing the Tumor Microenvironment in CLL: The Role of NK Cells and Prognostic Gene Markers
Xiaosheng Fang
Favorite
Fang, Yiqian

BeOne Medicines Ltd
1514 - Updated Results From the Phase 1 Study of Sonrotoclax (BGB-11417), a Novel B-Cell Lymphoma 2 Inhibitor, in Combination With Zanubrutinib for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Demonstrate Deep and Durable Responses
Yiqian Fang
Favorite
Fan, Lei

the First Affiliated Hospital with Nanjing Medical University
1008 - Clinical characteristics and outcome of chronic lymphocytic leukemia patients with renal involvement in the era of target drugs
Lei Fan
Favorite
1112 - Artificial Intelligence–Driven Clustering of Peripheral Blood Cell Morphology Reveals Disease Heterogeneity and Prognostic Relevance in CLL
Lei Fan
Favorite
1117 - The clinical significance of specific SF3B1 mutation variants in Chinese patients with chronic lymphocytic leukemia
Lei Fan
Favorite
1120 - Serum LC-MS based untargeted metabolomics machine learning for distinguishing asymptomatic and symptomatic CLL/SLL and predicting TTFT
Lei Fan
Favorite
1429 - Orelabrutinib, fludarabine, cyclophosphamide and obinutuzumab (OFCG) for first-line treatment of chronic lymphocytic leukemia: a multicenter, investigator-initiated phase II trial (cwcll-001 trial)
Lei Fan
Favorite
1603 - Single-cell transcriptome analysis reveals molecular mechanism of stem-like cells in Richter Transformation
Lei Fan
Favorite
1702 - Immune Cytopenia with Chronic Lymphocytic Leukemia: A Real-World Clinical Characteristic Analysis
Lei Fan
Favorite
1710 - A nomogram for survival prediction based on socioeconomic factors in patients with chronic lymphocytic leukemia: an analysis of SEER database
Lei Fan
Favorite
Farè, Silvia

Department of Chemistry, Materials and Chemical Engineering, Politecnico di Milano
1016 - Integrating phosphoproteomic analysis and innovative 3D cell culture systems to dissect the role of extracellular stiffness in CLL pathogenesis
Silvia Farè
Favorite
1202 - Advanced 3D culture system revealed the dynamic regulation of Podoplanin in CLL cells within the microenvironment
Silvia Farè
Favorite
Farina, Giuliana

13. Hematology and Medical Oncology, AORN Sant’Anna e San Sebastiano
1435 - Absence of lymphocytosis after starting treatment with cBTKi is a rare phenomenon except for trisomy 12 and CD49d positive CLL
Giuliana Farina
Favorite
Farooqui, Mohammed

Merck & Co., Inc.
1509 - Nemtabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Cohort J of the Phase 2 BELLWAVE-003 Study
Mohammed Farooqui
Favorite
1510 - BELLWAVE-010: An Open-Label, Phase 3 Study of Nemtabrutinib Plus Venetoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Mohammed Farooqui
Favorite
1511 - Nemtabrutinib in Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Phase 3 BELLWAVE-011 Study
Mohammed Farooqui
Favorite
Fazzi, Rita

Azienda Ospedaliera Universitaria Pisana
1708 - Chronic Obstructive Pulmonary Disease and Previous Pneumonia have an impact on infectious complications in patients with Chronic Lymphocytic Leukemia treated with Acalabrutinib and Zanubrutinib: a Multicentre SEIFEM Study.
Rita Fazzi
Favorite
Feng, Ru

Department of Hematology, Nanfang Hospital, The Southern Medical University
1408 - Optimizing Time-Limited Therapy in Unfit CLL/SLL Patients: Orelabrutinib, Bendamustine, and Obinutuzumab Combination (OBG) Regimen
Ru Feng
Favorite
Fernández de Larrea, Carlos

Hospital Clinic de Barcelona
1905 - Academic CD19-directed CAR-T ARI-0001 (varnimcabtagene autoleucel) for patients with relapsed/refractory chronic lymphocytic leukemia and Richter’s transformation
Carlos Fernández de Larrea
Favorite
Fernández-Rego, Adrián

Department of Immunology and Oncology, Centro Nacional de Biotecnologia (CNB)-CSIC, Madrid, Spain
1221 - The Integrin Adaptor Kindlin-3 Regulates Chronic Lymphocytic Leukemia Development and Progression
Adrián Fernández-Rego
Favorite
Fernandes, João Paulo

Hospital CUF Descobertas
1520 - Unveiling the journey of Chronic Lymphocytic Leukemia patients in Portugal: insights into the Rituximab-Venetoclax protocol
João Paulo Fernandes
Favorite
Fernandes, Stacey

Department of Medical Oncology, Dana-Farber Cancer Institute
1001 - IgM Monoclonal Gammopathy Arises Directly from MBL/CLL Cells: Evidence from Proteomic Analyses
Stacey Fernandes
Favorite
1009 - Epigenetic and transcriptional single-cell profiling reveals CLL-like states in low-count MBL
Stacey Fernandes
Favorite
Fernandez, Gabriel

Institut Pasteur de Montevideo
1018 - Unraveling the NOTCH1/MSI2/c-MYC Signaling Pathway Reveals a Novel Vulnerability in Chronic Lymphocytic Leukemia Progression
Gabriel Fernandez
Favorite
Fernández-Guzmán, Patricia

Vall d'Hebron Institute of Oncology (VHIO)
1019 - Immunological Landscape of CLL Development and Response to Early BTK Inhibition in del(13q14) Mice
Patricia Fernández-Guzmán
Favorite
1212 - High-dimensional profiling of CLL and T cell interactions during early phase of disease using a 42-color full-spectrum cytometry panel
Patricia Fernández-Guzmán
Favorite
Ferrà, Christelle

Department of Hematology, Hospital del Mar, Barcelona, Spain
1106 - Genomic characterization of chronic lymphocytic leukemia patients with TP53 alterations from a spanish real-world cohort treated with targeted agents
Christelle Ferrà
Favorite
1118 - Optical genome mapping identifies a high number of chromoanagenesis events in chronic lymphocytic leukemia patients with altered TP53
Christelle Ferrà
Favorite
Ferrajoli, Alessandra

UT MD Anderson Cancer Center
1401 - Risk of Second Primary Malignancies in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Receiving First-line Therapy: A Real-World Study
Alessandra Ferrajoli
Favorite
1712 - Other Cancers in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Alessandra Ferrajoli
Favorite
1714 - Trends and Predictors of Engagement in Preventive Health Measures in Patients with Chronic Lymphocytic Leukemia: A Prospective Analysis of Vaccinations and Cancer Screening Practices
Alessandra Ferrajoli
Favorite
Ferrant, Emmanuelle

CHU de Lyon-Sud
1413 - A fixed-duration, chemo-sparing approach in CLL: 8-year results of the phase 2 ICLL-07 FILO trial
Emmanuelle Ferrant
Favorite
1420 - Combination of Zanubrutinib + Venetoclax for Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results in SEQUOIA Arm D
Emmanuelle Ferrant
Favorite
Ferrara, Felicetto

AORN Antonio Cardarelli
1709 - Impact of Dose Intensity of Ibrutinib on Clinical Outcomes of CLL Patients: Analysis of the EVIdeNCE Study
Felicetto Ferrara
Favorite
Ferrarini, Isacco

Hematology Unit, Section of Biomedicine of Innovation, Department of Engineering for Innovation Medicine, University of Verona
1435 - Absence of lymphocytosis after starting treatment with cBTKi is a rare phenomenon except for trisomy 12 and CD49d positive CLL
Isacco Ferrarini
Favorite
1602 - Venetoclax in combination with chemotherapy in Richter Syndrome patients: a real-life experience
Isacco Ferrarini
Favorite
Ferrarini, Manlio

Università degli studi di Genova
1304 - Linking Cytokine Signaling and Metabolism in Chronic Lymphocytic Leukemia: The Translational Relevance of the IL-12 Family
Manlio Ferrarini
Favorite
Ferrario, Andrea

Division of Hematology, ASST Sette Laghi, Ospedale di Circolo, Varese
1403 - Factors Influencing the Regimen choice for firSt-line Therapy in Chronic Lymphocytic Leukemia: the FIRST-CLL study
Andrea Ferrario
Favorite
1907 - Autoimmune cytopenias in patients with chronic lymphocytic leukemia receiving acalabrutinib treatment.
Andrea Ferrario
Favorite
Ferreira, Antonio

Harvard Medical School/ Brigham and Women's Hospital
1305 - CLECL1⁺ Proliferative CLL Cells Remodel the Lymph Node Microenvironment Through Fibroblast Reprogramming, Th2 Polarization, and M2 Macrophage Induction to Promote Immune Evasion and Disease Progression
Antonio Ferreira
Favorite
Ferrer Lores, Blanca

Hematology Service, Valencia University Clinical Hospital
1115 - Clonal Evolutionary Dynamics Shaped by Genetic Profiles in Chronic Lymphocytic Leukemia: A New Era in Disease Monitoring and Therapy Resistance
Blanca Ferrer Lores
Favorite
1116 - IGHV Next-Generation Sequencing in CLL: Integrating Mutational Status and Clonotype Tracking for MRD Assessment
Blanca Ferrer Lores
Favorite
Ferrer, Ana

Hematological Cytology Laboratory, Pathology Department, Hospital del Mar and Translational Research on Hematological Neoplasms Group, Cancer Research Programme, Hospital del Mar Research Institute
1118 - Optical genome mapping identifies a high number of chromoanagenesis events in chronic lymphocytic leukemia patients with altered TP53
Ana Ferrer
Favorite
Ferrer, Gerardo

Josep Carreras Leukemia Research Institute
1018 - Unraveling the NOTCH1/MSI2/c-MYC Signaling Pathway Reveals a Novel Vulnerability in Chronic Lymphocytic Leukemia Progression
Gerardo Ferrer
Favorite
Ferrer-Lores, Blanca

Department of Hematology, Hospital Clínico Universitario-INCLIVA
1106 - Genomic characterization of chronic lymphocytic leukemia patients with TP53 alterations from a spanish real-world cohort treated with targeted agents
Blanca Ferrer-Lores
Favorite
1111 - Functional analysis of in-frame variants in TP53 gene identified in adult leukemias: A study of the TP53 Network of European Research Initiative on CLL
Blanca Ferrer-Lores
Favorite
1118 - Optical genome mapping identifies a high number of chromoanagenesis events in chronic lymphocytic leukemia patients with altered TP53
Blanca Ferrer-Lores
Favorite
Ferrero, Ainara

Hospital Universitari Arnau de Vilanova, Lleida
1106 - Genomic characterization of chronic lymphocytic leukemia patients with TP53 alterations from a spanish real-world cohort treated with targeted agents
Ainara Ferrero
Favorite
1118 - Optical genome mapping identifies a high number of chromoanagenesis events in chronic lymphocytic leukemia patients with altered TP53
Ainara Ferrero
Favorite
Ferrero, Fabiana

Department of Experimental Medicine, University of Genoa; IRCCS Ospedale Policlinico San Martino
1304 - Linking Cytokine Signaling and Metabolism in Chronic Lymphocytic Leukemia: The Translational Relevance of the IL-12 Family
Fabiana Ferrero
Favorite
Festari, María Florencia

Immunobiology Department, School of Medicine, University of the Republic, Montevideo, Uruguay
1211 - Unraveling a poor-prognosis CLL subgroup: from IGHV bias and AID activation to altered T-cell profiles
María Florencia Festari
Favorite
Feugier, Pierre

CHU nancy
1413 - A fixed-duration, chemo-sparing approach in CLL: 8-year results of the phase 2 ICLL-07 FILO trial
Pierre Feugier
Favorite
1521 - Real-world efficacy and safety of venetoclax +/- rituximab in >75-years old patients or with cardiovascular comorbidities and R/R chronic lymphocytic leukemia: interim results of the VERONE study
Pierre Feugier
Favorite
Feyzi, Emadoldin

Department of Hematology, St. Olavs University Hospital, Trondheim, Norway
1416 - CLL18 / MOIRAI: an international phase-III trial aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes in first-line treatment of CLL/SLL
Emadoldin Feyzi
Favorite
Fiallo Suarez, Dolly

Hospital Universitario de Gran Canaria Dr. Negrín
1109 - Integrating clinical and genomic factors to predict time to first treatment in chronic lymphocytic leukemia
Dolly Fiallo Suarez
Favorite
Filip, Daniel

Dept of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Rep.; CEITEC, Masaryk University
1017 - Long Non-Coding RNA LINC00173 Regulates BCR Signaling Propensity and mRNA Translation via Ribonucleoprotein Granules in CLL Cells
Daniel Filip
Favorite
1201 - IFNγ/IL21-JAK-STAT1 Signaling Axis Drives T-Cell–Mediated CLL Proliferation and Venetoclax Resistance
Daniel Filip
Favorite
Fink, Anna-Maria

Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University Hospital
1416 - CLL18 / MOIRAI: an international phase-III trial aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes in first-line treatment of CLL/SLL
Anna-Maria Fink
Favorite
1425 - IGLV3-21R110 as a prognostic marker for early stage CLL patients – clinical implications in patients treated with BTK inhibitors and diagnostic challenges
Anna-Maria Fink
Favorite
1442 - NGS-based MRD assessment refines prognostication after venetoclax-based first-line combinations for chronic lymphocytic leukemia: A prospective analysis of the phase 3 GAIA/CLL13 trial
Anna-Maria Fink
Favorite
1515 - Re-Treatment with Venetoclax-Obinutuzumab after time-limited, MRD-guided Venetoclax-Obinutuzumab: final analysis of 7 patients with chronic lymphatic leukemia (CLL) treated in the CLL2-BAG trial of the GCLLSG.
Anna-Maria Fink
Favorite
Fioribello, Erika

S.S.D. Microcitemia, anemie congenite e dismetabolismo del ferro, E. O. Ospedali Galliera & Clinic of Hematology, Department of Internal Medicine and Medical Specialties, University of Genoa
1403 - Factors Influencing the Regimen choice for firSt-line Therapy in Chronic Lymphocytic Leukemia: the FIRST-CLL study
Erika Fioribello
Favorite
Fischer von Weikersthal, Ludwig

Gesundheitszentrum St. Marien, Amberg, Germany
1515 - Re-Treatment with Venetoclax-Obinutuzumab after time-limited, MRD-guided Venetoclax-Obinutuzumab: final analysis of 7 patients with chronic lymphatic leukemia (CLL) treated in the CLL2-BAG trial of the GCLLSG.
Ludwig Fischer von Weikersthal
Favorite
Fischer, Kirsten

Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University Hospital
1104 - A Multi-Gene Expression-Based Prognostic Model for Risk Stratification in Chronic Lymphocytic Leukemia (CLL)
Kirsten Fischer
Favorite
1108 - CLL10000: Robust Classification of 1172 ATM Variants employing a Five-Factor Score derived from matched Non-Tumor Controls
Kirsten Fischer
Favorite
1416 - CLL18 / MOIRAI: an international phase-III trial aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes in first-line treatment of CLL/SLL
Kirsten Fischer
Favorite
1418 - A Refined Continuous Individualized Risk Index (CIRI2-CLL) for Accurately Predicting Outcomes after Limited-Duration CLL Therapy
Kirsten Fischer
Favorite
1425 - IGLV3-21R110 as a prognostic marker for early stage CLL patients – clinical implications in patients treated with BTK inhibitors and diagnostic challenges
Kirsten Fischer
Favorite
1442 - NGS-based MRD assessment refines prognostication after venetoclax-based first-line combinations for chronic lymphocytic leukemia: A prospective analysis of the phase 3 GAIA/CLL13 trial
Kirsten Fischer
Favorite
1515 - Re-Treatment with Venetoclax-Obinutuzumab after time-limited, MRD-guided Venetoclax-Obinutuzumab: final analysis of 7 patients with chronic lymphatic leukemia (CLL) treated in the CLL2-BAG trial of the GCLLSG.
Kirsten Fischer
Favorite
Fisher, Amelia

University of Leeds, Leeds UK
1705 - Inequalities in the diagnosis and survival of 30,071 people consecutively diagnosed with chronic lymphocytic leukaemia in England between 2014 and 2021: preliminary analysis from the UNCOVER Study Group
Amelia Fisher
Favorite
Fitoussi, Olivier

Polyclinique Bordeaux Nord Aquitaine
1704 - Feasibility of an individualized physical activity Intervention in CLL patients receiving ibrutinib +/-venetoclax: preliminary results from the QOLIBRI Study
Olivier Fitoussi
Favorite
Fitzgerald, Jennifer

BeOne Medicines Ltd
1706 - A Qualitative Study to Explore the Patient Experience of Continuous Covalent Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Study Methodology
Jennifer Fitzgerald
Favorite
Fitzgerald, Logan

The Ohio State University
1439 - Ten-year follow-up of a phase II study of ibrutinib in relapsed/ refractory chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL)
Logan Fitzgerald
Favorite
Fleury, Isabelle

Hôpital Maisonneuve-Rosemont, University of Montreal
1803 - Real-world Treatment Outcomes among Patients with High-Risk CLL/SLL Receiving Venetoclax-Based Therapy in 1L or 2L: An Updated International Study
Isabelle Fleury
Favorite
Flinn, Ian

Tennessee Oncology/OneOncology
1419 - SEQUOIA 5-year Follow-up in Arm C: Frontline Zanubrutinib Monotherapy in Patients with del(17p) and Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Ian Flinn
Favorite
1420 - Combination of Zanubrutinib + Venetoclax for Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results in SEQUOIA Arm D
Ian Flinn
Favorite
1524 - Patient-Reported Outcomes (PRO) among Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) receiving Pirtobrutinib: Final Analysis from the BRUIN Phase 1/2 Study
Ian Flinn
Favorite
Flinn, Joseph Casey

Dana-Farber Cancer Institute
1001 - IgM Monoclonal Gammopathy Arises Directly from MBL/CLL Cells: Evidence from Proteomic Analyses
Joseph Casey Flinn
Favorite
Florido, Yanira

Hospital Universitario de Gran Canaria Dr. Negrín
1109 - Integrating clinical and genomic factors to predict time to first treatment in chronic lymphocytic leukemia
Yanira Florido
Favorite
Foà, Robin

Hematology, Department of Translational and Precision Medicine, Sapienza University
1107 - Dissecting clonal hematopoiesis in the myeloid compartment of chronic lymphocytic leukemia and Richter transformation
Robin Foà
Favorite
1902 - Impact of treatment with ibrutinib or venetoclax on CAR-T cell generation in patients with chronic lymphocytic leukemia. Interim analysis of the GIMEMA CLL2020 study
Robin Foà
Favorite
Foglietta, Myriam

Azienda Santa Croce e Carle
1403 - Factors Influencing the Regimen choice for firSt-line Therapy in Chronic Lymphocytic Leukemia: the FIRST-CLL study
Myriam Foglietta
Favorite
Foraker, Narcy

OHSU
1432 - Title: A phase Ib study evaluating the safety and efficacy of tafasitamab, acalabrutinib, and obinutuzumab (TAO) in previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma
Narcy Foraker
Favorite
Forcade, Edouard

CHU Bordeaux, Hopital Haut-Leveque
1507 - Allogeneic stem cell transplantation is effective after pathway inhibitor treatments in CLL – a retrospective study on behalf of the Chronic Malignancies Working Party of EBMT
Edouard Forcade
Favorite
Forconi, Francesco

University Hospital Southampton NHS Trust
1433 - Ibrutinib plus venetoclax with measurable residual disease-guided duration of treatment is superior to both ibrutinib monotherapy and fludarabine-cyclophosphamide-rituximab for previously untreated chronic lymphocytic leukaemia: Report of the Phase III UK NCRI FLAIR study.
Francesco Forconi
Favorite
1506 - Bexobrutideg (NX-5948), a novel Bruton’s tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in relapsed/refractory CLL: updated findings from an ongoing Phase 1a study
Francesco Forconi
Favorite
Ford, Josie

Center for Lymphoma, Massachusetts General Hospital Cancer Center
1517 - Central nervous system involvement in chronic lymphocytic leukemia: a real-world analysis
Josie Ford
Favorite
Fornecker, Luc Matthieu

CHU Strasbourg
1413 - A fixed-duration, chemo-sparing approach in CLL: 8-year results of the phase 2 ICLL-07 FILO trial
Luc Matthieu Fornecker
Favorite
Forster, Jennifer

Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria; Salzburg Cancer Research Institute - Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Salzburg, Austria; Cancer Cluster Salzburg, Salzburg, Austria
1105 - Defining Signalotypes in Chronic Lymphocytic Leukemia and Applying Machine Learning to Better Characterize Biological and Clinical Subgroups
Jennifer Forster
Favorite
Forsyth, Colin

The Max Foundation
2003 - Evaluating Gaps and Opportunities in Chronic Lymphocytic Leukemia Treatment Access: Institutional Capacity Assessments in 18 LMICs
Colin Forsyth
Favorite
Fox, Christopher

Organization
1433 - Ibrutinib plus venetoclax with measurable residual disease-guided duration of treatment is superior to both ibrutinib monotherapy and fludarabine-cyclophosphamide-rituximab for previously untreated chronic lymphocytic leukaemia: Report of the Phase III UK NCRI FLAIR study.
Christopher Fox
Favorite
Franceschini, Erin

Pharmacyclics LLC, an AbbVie Company
1409 - Factors influencing physician’s choice of fixed-duration ibrutinib+venetoclax or continuous ibrutinib monotherapy in the treatment of patients with previously untreated CLL: physician questionnaire results from the prospective phase 2 TAILOR study
Erin Franceschini
Favorite
Franch, Andrea

Hospital Clinic de Barcelona
1905 - Academic CD19-directed CAR-T ARI-0001 (varnimcabtagene autoleucel) for patients with relapsed/refractory chronic lymphocytic leukemia and Richter’s transformation
Andrea Franch
Favorite
Francis, Anne

University of Oxford
1711 - A 3 week pause versus continued BTKi during vaccination (IMPROVE): a randomised, open-label, superiority trial.
Anne Francis
Favorite
Freilone, Roberto

Division of Hematology, A.O.U. CIttà della Salute e della Scienza di Torino
1403 - Factors Influencing the Regimen choice for firSt-line Therapy in Chronic Lymphocytic Leukemia: the FIRST-CLL study
Roberto Freilone
Favorite
Frenquelli, Michela

IRCCS Ospedale San Raffaele
1014 - Highlighting a crucial role for EGR2 mutations in CLL pathogenesis and BTKi resistance
Michela Frenquelli
Favorite
Fresa, Alberto

Hematology-Oncology and Stem-Cell Transplantation Unit Department of Onco-Hematology and Innovative Diagnostics Istituto Nazionale Tumori IRCCS - Fondazione G.Pascale
1022 - Unravelling the Clinical and Biological Features of Accelerated Chronic Lymphocytic Leukemia
Alberto Fresa
Favorite
1220 - Chronic Lymphocytic Leukemia and Renal Cell Carcinoma: A Case Series of Twelve Patients
Alberto Fresa
Favorite
Fric, Jan

ICRC St. Anne's University Hospital
1017 - Long Non-Coding RNA LINC00173 Regulates BCR Signaling Propensity and mRNA Translation via Ribonucleoprotein Granules in CLL Cells
Jan Fric
Favorite
Friedman, Matthew

Hosftra University
1208 - Selectively targeting foreign antigen to surface membrane IgD leads to enhanced T-cell activation in patients with CLL and normal people
Matthew Friedman
Favorite
FRIGERI, Ferdinando

AORN S.ANNA E SAN SEBASTIANO CASERTA
1709 - Impact of Dose Intensity of Ibrutinib on Clinical Outcomes of CLL Patients: Analysis of the EVIdeNCE Study
Ferdinando FRIGERI
Favorite
Frustaci, Anna Maria

ASST Grande Ospedale Metropolitano Niguarda
1402 - Cytogenetic instability and therapeutic pressure in Fixed vs Continuous regimens for Chronic Lymphocytic Leukemia after first line treatment: Preliminary Data from an Italian Multicenter Experience
Anna Maria Frustaci
Favorite
1403 - Factors Influencing the Regimen choice for firSt-line Therapy in Chronic Lymphocytic Leukemia: the FIRST-CLL study
Anna Maria Frustaci
Favorite
1525 - Updated Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the Ongoing Phase 1 CaDAnCe-101 Study
Anna Maria Frustaci
Favorite
1708 - Chronic Obstructive Pulmonary Disease and Previous Pneumonia have an impact on infectious complications in patients with Chronic Lymphocytic Leukemia treated with Acalabrutinib and Zanubrutinib: a Multicentre SEIFEM Study.
Anna Maria Frustaci
Favorite
1907 - Autoimmune cytopenias in patients with chronic lymphocytic leukemia receiving acalabrutinib treatment.
Anna Maria Frustaci
Favorite
Fuentes Trillo, Azahara

Human Technopole, Milan 20157, Italy
1115 - Clonal Evolutionary Dynamics Shaped by Genetic Profiles in Chronic Lymphocytic Leukemia: A New Era in Disease Monitoring and Therapy Resistance
Azahara Fuentes Trillo
Favorite
1116 - IGHV Next-Generation Sequencing in CLL: Integrating Mutational Status and Clonotype Tracking for MRD Assessment
Azahara Fuentes Trillo
Favorite
Fujimori, Toshifumi

AstraZeneca
1424 - Safety Analysis of Fixed-Duration Acalabrutinib-Venetoclax Combinations vs Chemoimmunotherapy: A Post Hoc Analysis From the Phase 3 AMPLIFY Trial
Toshifumi Fujimori
Favorite
Fumagalli, Lorenzo

Division of Hematopathology, IEO
1107 - Dissecting clonal hematopoiesis in the myeloid compartment of chronic lymphocytic leukemia and Richter transformation
Lorenzo Fumagalli
Favorite
Fu, Qianhong

BeOne Medicines Ltd
1401 - Risk of Second Primary Malignancies in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Receiving First-line Therapy: A Real-World Study
Qianhong Fu
Favorite
1410 - Impact of testing for genetic markers on treatment selection and clinical outcomes among patients with chronic lymphocytic leukemia
Qianhong Fu
Favorite
1411 - Outcomes, inequities, and access to front-line preferred therapies for chronic lymphocytic leukemia in the United States: a real-world evidence study
Qianhong Fu
Favorite
1528 - Estimating the Cardiac Deaths Associated with Treating Chronic Lymphocytic Leukemia with Ibrutinib versus Zanubrutinib in the United States
Qianhong Fu
Favorite
Furnback, Wesley

Real Chemistry
1436 - Real-World Treatment Utilization Patterns, Discontinuation and Healthcare Resource Utilization of First-Line (1L) Bruton Tyrosine Kinase Inhibitor (BTKi) Therapy in Chronic Lymphocytic Leukemia (CLL): Age-Related Disparity
Wesley Furnback
Favorite